Bing

SEARCH HISTORY

Corbus' common stock was uplisted to the NASDAQ Capital Market from the ... Ligand Pharmaceuticals Inc.'s (LGND) phase Ib clinical trial with investigational diabetes drug LGD-6972 at dosages of 5mg, 10mg and 15mg has demonstrated favorable safety ...
Realtime Business News · 6/8/2015
In the first three weeks of October various FDA reviews are due for Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Inc. (NASDAQ: LGND), followed by Antares ... and its 52-week trading range for its stock is $14.75 to $50.85. Antares Pharma Inc ...
24/7 Wall ST · 10/1/2013
Lemelson Capital Management Further Increases Short Position in Ligand Pharmaceuticals (NASDAQ: LGND), Updates LGND Research Report ... 2014 research reports on the stock. oLemelson Capital's original June 16, 2014 report can be found here.
Bloomberg · 8/4/2014
More from Bing News
The biotech stock slingshot: Optimism about growth and M&A speculation ... small cap biotechs such as Emergent BioSolutions (EBS) and Ligand (LGND) as well as biotech blue chips Biogen and Celgene. Still, investors must remember that biotech is …
CNN Money · ByPaul R. La · 6/10/2014
Health-care stocks have fared quite well so far this year ... develops cancer-fighting medications and hematology drugs. The stock has been the second weakest performer among the eight health-care names listed here, down 22% this year through Friday ...
Market Watch · 8/5/2014
Shares of Ligand Pharmaceuticals Inc ... The stock has a 52-week low of 41.99. The 30-day simple moving average of 53.65 is lower than the 60-day simple moving average of 54.21. The trading currency is in USD. Ligand Pharmaceuticals Inc. (NASDAQ …
rockhilldaily.com · 2/2/2015
Spectrum has also licensed from Ligand Pharmaceuticals (LGND) captisol-enabled Melphalan for ... who rates the stock a buy. He puts the stock’s worth at $15 a share. Noting that biotech acquisitions continue to rise, Benjamin says other companies in ...
Forbes · ByGene Marcial · 5/14/2014
Heartware International (HTWR) – The company’s shares plunged 0.5 pct. Ligand Pharmaceuticals Inc (LGND) – The company’s stocks declined 0.5 pct. Pdl Biopharma (PDLI) – The company’s shares fell 0.4 pct.
Fx Pips · 4/21/2015
Short term price target: $4.25 Midterm price target: $7.00 At the time of my write-up the stock was trading at $3.69 a share. My goal of $7 was reached long in advance of the actual decision, in which LODOTRA gained FDA approval. However, after trading as ...
Trefis · 11/13/2012
Prior to Senomyx, he was Chief Operating Officer of Pharmacopeia, Inc., a drug discovery company that was acquired by Ligand Pharmaceuticals, Inc. (NASDAQ: LGND), and President ... The holders of the Company’s preferred stock entered into a …
Business Wire · 1/20/2012